Here are four things to know:
1. Brean Capital currently has a “buy” rating on the stock.
2. NuVasive has a one-year low of $31.35 and a one-year high of $51.23.
3. The stock has a 50-day moving average of $47.23 and a 200-day moving average of $41.65.
4. NuVasive’s market cap is $2.139 billion.
More articles on devices:
Spine device company stock report: 5 key companies — Feb. 26
Invibio Spine’s PEEK-OPTIMA HA Enhanced shows promise
JMEA Corporation wins grant from Montgomery County’ economic development department
